Cencora, Inc. $COR Stock Position Lifted by American Institute for Advanced Investment Management LLP

American Institute for Advanced Investment Management LLP grew its stake in shares of Cencora, Inc. (NYSE:COR) by 1.1% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,787 shares of the company’s stock after buying an additional 160 shares during the period. Cencora accounts for 3.0% of American Institute for Advanced Investment Management LLP’s portfolio, making the stock its 6th biggest holding. American Institute for Advanced Investment Management LLP’s holdings in Cencora were worth $4,434,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Voleon Capital Management LP bought a new stake in Cencora during the 1st quarter valued at approximately $3,111,000. Focus Partners Wealth increased its position in shares of Cencora by 25.8% during the 1st quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock valued at $1,589,000 after purchasing an additional 1,171 shares during the last quarter. Martin Capital Partners LLC increased its position in shares of Cencora by 205.2% during the 2nd quarter. Martin Capital Partners LLC now owns 3,784 shares of the company’s stock valued at $1,135,000 after purchasing an additional 2,544 shares during the last quarter. Fiduciary Alliance LLC bought a new position in shares of Cencora during the 2nd quarter valued at approximately $262,000. Finally, Ascent Group LLC increased its position in shares of Cencora by 42.7% during the 1st quarter. Ascent Group LLC now owns 12,586 shares of the company’s stock valued at $3,500,000 after purchasing an additional 3,764 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Insider Activity at Cencora

In related news, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the sale, the chief executive officer owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. This trade represents a 11.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the sale, the chairman directly owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. This trade represents a 9.30% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 41,544 shares of company stock valued at $12,230,941. Insiders own 10.80% of the company’s stock.

Cencora Stock Down 1.1%

Shares of COR stock opened at $337.60 on Friday. The stock’s 50-day simple moving average is $308.09 and its 200-day simple moving average is $297.11. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. The firm has a market capitalization of $65.45 billion, a PE ratio of 34.73, a P/E/G ratio of 1.56 and a beta of 0.63. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $350.46.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, August 6th. The company reported $4.00 EPS for the quarter, topping analysts’ consensus estimates of $3.79 by $0.21. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The firm had revenue of $80.66 billion for the quarter, compared to the consensus estimate of $80.34 billion. During the same quarter in the prior year, the business earned $3.34 earnings per share. The company’s revenue was up 8.7% compared to the same quarter last year. Equities analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were given a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.7%. The ex-dividend date was Friday, August 15th. Cencora’s dividend payout ratio (DPR) is 22.63%.

Analysts Set New Price Targets

A number of research firms recently issued reports on COR. Weiss Ratings restated a “buy (b-)” rating on shares of Cencora in a report on Thursday. Mizuho upped their target price on Cencora from $334.00 to $340.00 and gave the stock an “outperform” rating in a report on Thursday. Morgan Stanley set a $330.00 price target on Cencora and gave the stock an “equal weight” rating in a research report on Wednesday, July 16th. Wall Street Zen lowered Cencora from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Finally, Wells Fargo & Company boosted their price target on Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 13th. Nine analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, Cencora has a consensus rating of “Moderate Buy” and an average price target of $329.55.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.